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Abstract 
Mucopolysaccharidosis IIIB is a paediatric lysosomal storage disease caused by deficiency of 
the enzyme α-N-acetylglucosaminidase (NAGLU), involved in the degradation of the 
glycosaminoglycan heparan sulphate. Absence of NAGLU leads to accumulation of partially 
degraded heparan sulphate within lysosomes and the extracellular matrix, giving rise to severe 
central nervous system degeneration with progressive cognitive impairment and behavioural 
problems. There are no therapies. Haematopoietic stem cell transplant shows great efficacy in 
the related disease mucopolysaccharidosis I, where donor-derived monocytes can transmigrate 
into the brain following bone marrow engraftment, secrete the missing enzyme and cross-
correct neighbouring cells. However, little neurological correction is achieved in 
mucopolysaccharidosis IIIB patients. We have therefore developed an ex vivo haematopoietic 
stem cell gene therapy approach in a mouse model of mucopolysaccharidosis IIIB, utilising a 
high-titre lentiviral vector and the myeloid-specific CD11b promoter, driving the expression of 
NAGLU (LV.NAGLU). In order to understand the mechanism of correction we also compared 
this with a poorly secreted version of NAGLU containing a C-terminal fusion to IGFII 
(LV.NAGLU-IGFII). Mucopolysaccharidosis IIIB haematopoietic stem cells were transduced 
with vector, transplanted into myeloablated mucopolysaccharidosis IIIB mice and compared at 
8 months of age with mice receiving a wild-type transplant. As the disease is characterised by 
increased inflammation, we also tested the anti-inflammatory steroidal agent prednisolone 
alone, or in combination with LV.NAGLU, to understand the importance of inflammation on 
behaviour. NAGLU enzyme was substantially increased in the brain of LV.NAGLU and 
LV.NAGLU-IGFII-treated mice, with little expression in wild-type bone marrow transplanted 
mice. LV.NAGLU treatment led to behavioural correction, normalisation of heparan sulphate 
and sulphation patterning, reduced inflammatory cytokine expression and correction of 
astrocytosis, microgliosis and lysosomal compartment size throughout the brain. The addition 
of prednisolone improved inflammatory aspects further. Substantial correction of lysosomal 
storage in neurons and astrocytes was also achieved in LV.NAGLU-IGFII-treated mice, despite 
limited enzyme secretion from engrafted macrophages in the brain. Interestingly both wild-
type bone marrow transplant and prednisolone treatment alone corrected behaviour, despite 
having little effect on brain neuropathology. This was attributed to a decrease in peripheral 
inflammatory cytokines. Here we show significant neurological disease correction is achieved 
using haematopoietic stem cell gene therapy, suggesting this therapy alone or in combination 
with anti-inflammatories may improve neurological function in patients. 
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Introduction 
Mucopolysaccharidosis IIIB (MPSIIIB or Sanfilippo B syndrome) is a neurodegenerative 
lysosomal storage disease caused by a deficiency in the glycosaminoglycan degrading enzyme, 
ɑ-N-acetylglucosaminidase (NAGLU). NAGLU deficiency results in the global accumulation 
of partially degraded heparan sulphate (HS) in cells, leading to cellular dysfunction which is 
particularly apparent in the brain. Symptom onset begins within the first two to four years of 
life, characterised by a plateau in development, speech delay, and worsening behavioural 
problems, together with minor somatic indicators such as organomegaly and facial dysmorphia. 
Progressive motor impairment follows leading to greatly shortened life expectancy. There are 
currently no effective treatments. 
Enzyme replacement therapy has successfully treated somatic disease in other MPS disorders. 
Cross-correction occurs via mannose-6-phosphate mediated enzyme uptake by deficient cells. 
However the inability of delivered enzyme cannot to cross the blood brain barrier limits its 
worth in MPSIIIB, where the main pathology is neurological. Approaches to deliver enzyme 
via an intracerebroventricular route are in progress, but these methods are invasive. A C-
terminal fusion of NAGLU to insulin-like growth factor 2 (rhNAGLU-IGFII), which also binds 
the mannose-6-phosphate-receptor leads to more efficient uptake, lysosomal targeting and 
activity following intracerebroventricular injection in MPSIIIB mice (Kan et al., 2014a; Kan 
et al., 2014b).  
Another option for MPSIIIB patients is delivery of adeno-associated virus (AAV) based gene 
therapy vectors via a variety of routes to treat the brain (Fu et al., 2002; Cressant et al., 2004; 
Fu et al., 2007; Fu et al., 2010). One hurdle in developing these therapies is achieving effective 
vector distribution from the sites of injection, something that can be effectively achieved in 
rodents but not in patients to date (Tardieu et al., 2014; Tardieu et al., 2017).  
Haematopoietic stem cell transplant (HSCT), enables donor HSCs to repopulate bone marrow 
(BM) of myeloablated recipients, with donor-engrafted leukocytes secreting enzyme to cross-
correct somatic cells. BM-derived monocytes are also able to cross the blood-brain barrier and 
engraft within the brain, enabling cross-correction within the central nervous system (CNS). 
Although effective in MPSI patients, several studies have shown poor neurological outcomes 
following HSCT in MPSIIIB patients (Vellodi et al., 1992; Shapiro et al., 1995), despite 
successful clearance of HS in somatic organs. This failure is thought to be due to poor 
endogenous secretion of NAGLU from engrafted donor macrophages in the brain. Cord blood 
transplantation has had greater success in MPSIIIB patients (Prasad et al., 2008), but behaviour 
is not corrected, despite improved survival. A retroviral mediated HSC gene therapy (HSCGT) 
approach in MPSIIIB mice, designed to overcome this failing was found to have disappointing 
efficacy and the effect reduced with time (Zheng et al., 2004).  
We have previously demonstrated in the clinically similar disease MPSIIIA, that ex vivo gene 
delivery of N-sulphoglucosamine sulphohydrolase (SGSH) to HSCs using a clinically 
approved lentiviral vector (LV), driven by the myeloid specific CD11b promoter, led to 
restoration of 11% wild-type (WT) activity of SGSH in the brains of MPSIIIA mice, 
normalised HS storage and CNS pathology and corrected behaviour (Sergijenko et al., 2013), 
whereas WT transplantation was unsuccessful (Langford-Smith et al., 2012). CD11b is highly 
expressed by monocyte/macrophage/microglial cells, leading to enhanced transgene 
expression in the brain compared to the ubiquitous phosphoglycerate kinase promoter. This 
approach is now under development for clinical trial (Bigger and Wynn, 2014). 
We applied this HSCGT methodology in the MPSIIIB mouse model, comparing MPSIIIB mice 
receiving WT HSCs versus MPSIIIB HSCs transduced with a vector expressing either NAGLU 
(LV.NAGLU) or a poorly secreted version of NAGLU fused to IGFII (LV. NAGLU-IGFII) 
(Kan et al., 2014b). This allowed us to study the role of NAGLU expressing donor 
macrophages in the brain, including the inflammatory cytokine/chemokine effects that they 
mediate, in the context of limited NAGLU secretion. 
There are several anti-inflammatories now used clinically to manage abnormal behaviour 
(Reale et al., 2012; Felger and Lotrich, 2013). Given that peripheral cytokines impact directly 
on brain pathology, prednisolone (PRED), a corticosteroid that has limited ability to cross the 
blood-brain barrier, was used to treat MPSIIIB mice to test the effect of somatic correction of 
inflammation on brain disease. Notably however, prednisolone is not recommended in patients 
due to significant side effects, not seen in rodents. A combined PRED and LV.NAGLU 
HSCGT group was also included. We demonstrate significantly increased brain NAGLU 
activity, normalised HS brain storage, reduced neuroinflammation and secondary storage and 
behavioural correction with LV-mediated HSCGT using both vectors, highlighting the 
effectiveness of our LV.NAGLU vector approach for correction of brain disease in MPSIIIB. 
No brain correction was seen following WT HSCT. PRED treatment additionally reduced 
somatic tissue inflammation, providing enhanced patient benefit when used in combination 
with LV.NAGLU HSCGT, but all treatments improved hyperactive behaviour. 
Materials and Methods 
Generation and in vitro testing of LV.NAGLU and LV.NAGLU-IGFII 
Codon optimised human NAGLU (GenBank® accession number NM_000263.3) flanked with 
attB1 and attB2 sites (manufactured by GeneArt) was cloned using the gateway system (Life 
Technologies) into the pCCL LV backbone downstream of the CD11b promoter (Sergijenko 
et al., 2013), to generate pCCLsin.cPPT.hCD11b.NAGLU.WPRE (LV.NAGLU). NAGLU-
IGFII fusion plasmid comprising full length NAGLU, a short unstructured linker, the c-Myc 
epitope EQKLISEED and amino acids 32-91 of IGFII (GenBank® accession number 
NM_001007139.4) was kindly donated by Patricia Dickson (Kan et al., 2014b). PCR, using 
extended primers designed to incorporate AttB1 and AttB2 sites either side of NAGLU-IGFII, 
was used to amplify the NAGLU-IGFII segment, which was then agarose gel purified and 
cloned using the gateway system into the LV genome plasmid described above to generate 
pCCLsin.cPPT.hCD11b.NAGLU-IGFII.WPRE (LV.NAGLU-IGFII). A GFP LV in the same 
vector backbone (pCCLsin.cPPT.hCD11b.eGFP) was used as a control (Langford-Smith et al., 
2012). LV was produced and titred as described previously (Langford-Smith et al., 2012; 
Sergijenko et al., 2013). CHME3 cells were transduced at a multiplicity of infection of 10, 
collecting media and cells after 48 hours. 
Mice, HSC isolation, transduction and transplantation 
All in vivo procedures were ethically approved in accordance with Home Office regulations. 
Mice were housed in a 12/12-hour light/dark cycle with food and water provided ad libitum. 
MPSIIIB (B6.129S6-Naglutm1Efn/J, strain 003827, Jackson Laboratory) mice were backcrossed 
with C57BL/6J mice (CD45.2) or B6.SJL-Ptprca Pepcb/BoyJ (strain 002014, Jackson 
Laboratory, CD45.1) mice to distinguish between donor and recipient haematopoietic cells. 
BM was isolated from donor CD45.1-MPSIIIB mice, lineage depleted and HSCs transduced 
with a multiplicity of infection of 60 as described previously (Langford-Smith et al., 2012). 
Recipient mice at 2 months of age were treated with intraperitoneal 125mg/kg busulfan 
(Busilvex; Pierre Fabre, Boulogne, France) over 5 days prior to tail vein injection of 3x105 LV-
transduced HSCs. Whole BM from CD45.1-WT mice (1x107) was injected into busulfan-
conditioned MPSIIIB mice for WT HSCT treated mice. PRED was added at 6mg/L (~1mg/kg 
per day) in drinking water from 6 weeks in control mice or 14 weeks following LV-mediated 
HSCGT. The survival curve was limited by home office licence regulations, meaning that mice 
had to be culled when they showed significant signs of disease; typically urine retention and 
loss of body condition. A cohort of untreated WT littermates suffered from alopecia (without 
other signs of distress) from 13 months, requiring sacrifice. 
Donor chimerism 
HSC engraftment was assessed in peripheral blood following staining with anti-mouse 
CD45.1-PE (donor) and CD45.2-FITC (recipient) (both BD Pharmingen) antibodies and 
analysed on a BD FACS Canto II flow cytometer. Animals where chimerism was below 60% 
were excluded. 
Tissue harvesting 
At 8-months of age, mice were anaesthetized, the right atrium cut to allow blood collection 
into citrate buffer for plasma and white blood cells (WBCs) and transcardially perfused with 
warmed PBS to remove blood, as described previously (Langford-Smith et al., 2012). One 
brain hemisphere and liver pieces were fixed in 4% paraformaldehyde for 24 hours, before 
washing with PBS. Brain hemispheres were placed into 30% sucrose 2mM MgCl2 for 24 hours 
before freezing at -80ºC for 30µm coronal microtomy. Liver was transferred into 70% ethanol 
for paraffin mounting and slicing. The second brain hemisphere and remaining organs were 
frozen at -80ºC. BM was isolated from the hind legs of mice and set up in MethoCult culture 
(Stem Cell Technologies) as previously described (Langford-Smith et al., 2012) to assess CFU 
lineage development.  
Vector copy number determination 
Vector copy number (VCN) was determined from harvested tissue using quantitative PCR as 
described (Langford-Smith et al., 2012). 
Enzyme assays 
Tissue was homogenised in 0.5M NaCl/0.02M Tris, 0.1% v/v Triton X-100, pH7-7.5, then 
centrifuged at 2200g, storing the supernatant. Protein concentration was determined using 
Pierce BCA assay kit (Fisher Scientific, Loughborough, UK). For NAGLU enzymatic assay, 
10-60μg of total protein was incubated with NAGLU substrate (4-methylumbelliferyl-N-
acetyl-α-D-glucosaminide, Sigma) for 4 hours at 37°C, resulting in release of fluorescent 4-
methylumbelliferone. Stop buffer (0.2M carbonate buffer, pH 9.5) was then added and the 
fluorescence measured immediately at excitation 360 nm and emission 460 nm using a Synergy 
HT Microplate reader (BioTec, Potton, UK) against known 4-methylumbelliferone standards. 
For assessment of β-Hex activity 1-2μg total protein was incubated with 4-Methylumbelliferyl-
N-acetyl-β-D-glucosaminide for 40 minutes at 37°C. Stop buffer was then added and the 
fluorescence measured. 
Glycosaminoglycan analysis 
Brain and liver samples were homogenised in PBS/1% Triton X-100 and a small sample taken 
for protein quantification. Tissues were digested with pronase (Roche) and 
glycosaminoglycans purified as described previously (Holley et al., 2011). Glycosaminoglycan 
samples were then divided into two; one aliquot was digested with heparinase I/II/III and 
labelled with 2-aminoacridone as described previously (Holley et al., 2011), the second was 
digested with 2mIU chondroitinase ABC (Sigma) and 2-aminoacridone labelled. Both HS and 
chondroitin sulphate/dermatan sulphate (CS/DS) disaccharides were subject to RP-HPLC 
using a Zorbax Eclipse XBD-C18 column (Agilent) equilibrated in 95% 0.1M ammonium 
acetate/5% acetonitrile, running on an Agilent 1200 Series HPLC system. Disaccharides were 
eluted over a 5-20% gradient of acetonitrile at 0.2 mL/min, detecting in-line fluorescence at 
excitation 425nm and emission 520nm. 2-aminoacridone-labelled CS/DS or HS disaccharide 
standards (Iduron) were used for peak identification. For calculation of µg HS or CS/DS, total 
fluorescence was compared with the fluorescence from known quantities of HS or DS. 
Correction factors were calculated (Supplementary Table 1) as described (Deakin and Lyon, 
2008). 
Measurement of cytokine/chemokine level 
MIP-1ɑ (CCL3), IL-1ɑ, MCP-1 (CCL2), KC (CXCL1) and RANTES (CCL5) were measured 
in brain, liver and plasma using Cytomeric Bead Array flex sets (BD Biosciences) according 
to manufacturer’s instructions. 
Open field behaviour 
Open field behaviour was performed as previously described (Langford-Smith et al., 2011a; 
Langford-Smith et al., 2011b). The data were analysed using Ethovision XT11.5 software 
(Noldus).  
Immunohistochemistry 
Free-floating immunohistochemistry was performed on seven coronal brain sections (30μm) 
from matched areas of Bregma (0.98, 0.14, −0.46, −1.06, −1.70, -2.40 and −3.28mm) as 
described previously (Malinowska et al., 2010; Sergijenko et al., 2013). Paraffin embedded 
liver sections (5µM) were dewaxed and rehydrated prior to staining, processing as above. 
Primary antibodies included rat anti-LAMP2 (Abcam), rabbit anti-NeuN (Abcam), peroxidase-
conjugated BSI-B4 (Sigma), rabbit anti-GFAP (DakoCytomation), and mouse anti-GM2 (a gift 
from Dr Konstantin Dobrenis); secondary antibodies included goat anti-rabbit Alexa Fluor® 
594, goat anti-rat Alexa Fluor® 488 (Life Technologies) and Biotinylated-goat anti-mouse IgM 
(Vector laboratories). DAPI was used to highlight nuclei. IB4 stained slides were 
counterstained with Mayer’s haemotoxylin. Images were acquired on a 3D-Histech 
Pannoramic-250 microscope slide-scanner using a 20x/0.30 Plan Achromat objective (Zeiss) 
and the DAPI, FITC and TRITC filter sets and processed using Case Viewer software (3D-
Histech).  
Experimental design 
Four experimental groups were compared against WT or MPSIIIB control mice. 14-22 mice 
were analysed for behaviour and 6-10 for biochemistry and histology. N numbers were based 
on previous power calculations as seen in the MPSIIIA mouse model (Sergijenko 2013) and 
behavioural changes in the MPSIIIB mouse model (Langford-Smith 2011). It was impossible 
to blind in vivo treatment groups, due to the nature of the mouse model, treatments given and 
experiment size, with transplants staggered over several months, yet treatment groups were 
filled equally to avoid bias. Analysis was carried out in a blinded fashion. 
Statistical analysis 
GraphPad Prism was used for one-way or two-way analysis of variance (ANOVA) and Tukey 
post hoc test for analysis. Significance was P<0.05%. 
Results 
Efficient expression of NAGLU from lentiviral vectors 
We constructed a lentiviral vector expressing either human NAGLU or human NAGLU fused 
to amino acids 32–91 of IGFII (Kan et al., 2014b), both under the control of the myeloid 
specific CD11b promoter (Fig. 1A). Over-expression of active NAGLU enzyme was confirmed 
in the human microglial cell line CHME3, using LV.eGFP as a control. Significant increases 
of 5.5-fold and 6.2-fold in intracellular NAGLU activity was seen with LV.NAGLU and 
LV.NAGLU-IGFII respectively (Fig. 1B), without noticeable toxicity. Secreted activity was 
increased 9.9-fold with LV.NAGLU but minimal secretion was observed with LV.NAGLU-
IGFII (Fig. 1C), providing us with a tool to study the effect of restricting NAGLU expression 
to engrafted cells, with little cross-correction of neighbouring cells. 
In order to determine whether ex vivo transduction of MPSIIIB HSCs can effectively treat the 
mouse model of MPSIIIB following transplant, we set up seven treatment groups in vivo (Fig. 
1D): 1) WT control, 2) MPSIIIB control, 3) WT HSCT in MPSIIIB mice, 4) LV.NAGLU-
transduced MPSIIIB HSCs in MPSIIIB, 5) LV.NAGLU-IGFII-transduced MPSIIIB HSCs in 
MPSIIIB, 6) PRED in MPSIIIB, and 7) LV.NAGLU-transduced MPSIIIB HSCs combined 
with PRED in MPSIIIB (PRED+LV.NAGLU). Thus groups 4, 5 and 7 (LV.NAGLU, 
LV.NAGLU-IGFII and PRED+LV.NAGLU) all received LV-mediated HSCGT. Although 
prednisolone has some deleterious effects in children, it was chosen over other anti-
inflammatories due to its ease of long-term administration in drinking water compared to the 
need for daily injections, and its previous efficacy in MPSIIIB animals (DiRosario et al., 2009). 
Average VCN measured in HSC-enriched BM at transplant was similar at 7.4-10.8 VCNs per 
cell (Fig. 1E). Consequently, NAGLU activity in HSC-enriched BM was substantially 
increased above WT levels in all LV-mediated HSCGT groups (8.4-fold over WT in 
LV.NAGLU, 8.9-fold in LV.NAGLU-IGFII, and 7.6-fold in PRED+LV.NAGLU) with no 
significant differences between groups (Fig. 1F). Equally there were no significant differences 
in the total number of CFUs or the proportion of each colony type obtained from WT, MPSIIIB 
or MPSIIIB HSCs transduced with either LV vector (Fig. 1G/H), suggesting no NAGLU or 
LV toxicity in HSCs. Over 82% donor peripheral blood chimerism was achieved in all 
transplant groups at 6 months of age, with no significant difference between groups (Fig. 1I).  
A proportion of mice in each group were culled at 8 months of age to assess efficiency of 
therapy. Remaining mice were kept for long-term analysis, sacrificing at their humane 
endpoint. Mean survival was 9.4 months in untreated MPSIIIB mice and PRED treated mice 
(Fig. 1J/K), typically due to urine retention as seen previously (Gografe et al., 2009). Survival 
was significantly increased in WT HSCT and LV-mediated HSCGT groups, with reduced 
incidence of urine retention.  
LV-mediated HSCGT results in significantly increased NAGLU activity compared 
to WT HSCT 
Mice sacrificed at 8 months of age were used for biochemical and immunohistological analysis. 
There was no significant difference in the total number of BM-derived CFUs (Supplementary 
Fig. 1A) or in the percentage of CFUs of different lineage types (Supplementary Fig. 1B) 
suggesting no toxicity of transgene or vector. 
VCN and NAGLU activity were measured in WBCs, plasma, BM, brain, spleen and liver (Fig. 
2). No significant differences in VCN were seen between LV-mediated HSCGT treatment 
groups in WBCs, BM, brain or liver, however in all organs tested there was a trend towards 
higher VCNs in the LV.NAGLU group versus PRED+LV.NAGLU (Fig. 2/Supplementary Fig. 
2). A significant difference between groups was seen in spleen, with 10 VCNs in the 
LV.NAGLU group compared to 4.3 in PRED+LV.NAGLU. This is likely due to the reduced 
VCN in transplanted HSCs between these groups (Fig. 1E). 
No detectable NAGLU enzyme activity was found in MPSIIIB tissues. All treatments except 
PRED increased NAGLU activity compared to untreated MPSIIIB. NAGLU activity was 
increased in WBCs to 221% of WT in WT HSCT animals, compared to 3741%, 1853% and 
1905% in LV.NAGLU, LV.NAGLU-IGFII and PRED+LV.NAGLU groups respectively (Fig. 
2B). Plasma NAGLU levels were 287% of WT with LV.NAGLU, but only 14% of WT was 
seen in LV.NAGLU-IGFII animals, suggesting little secretion of NAGLU-IGFII occurs in vivo 
(Fig. 2D), mirroring results in vitro (Fig. 1C). Little plasma NAGLU was apparent in WT 
HSCT animals, suggesting that native NAGLU secretion is low from haematopoietic cells. BM 
NAGLU activity was increased to 89% of WT with WT HSCT and 175% of WT in 
LV.NAGLU-IGFII (Fig. 2G). Substantially increased BM NAGLU levels were seen in 
LV.NAGLU and LV.NAGLU+PRED groups (1240% and 780% respectively). Positive 
correlations were seen between VCN and enzyme overexpression (Supplementary Fig. 2). 
Brain NAGLU activity was only increased significantly compared to MPSIIIB in LV-mediated 
HSCGT groups (Fig. 2J). 1.3% of WT NAGLU levels were seen with WT HSCT, compared 
to 13% with LV.NAGLU and 8.6% with LV.NAGLU-IGFII. 6.0% enzyme activity was 
achieved in PRED+LV.NAGLU groups, probably reflecting the respective VCN in 
transplanted HSCs (Fig. 2I, 1E). In spleen and liver, all treatments increased NAGLU enzyme 
levels, with the greatest correction achieved with HSCGT (Fig. 2M/P). 
Lysosomal function is important to maintain cellular homeostasis, with increased lysosomal 
size often leading to dysregulated expression of other lysosomal enzymes (Sardiello et al., 
2009). MPSIIIB mice exhibited increased β-Hex activity over WT in all tissues examined (Fig. 
2C/E/H/K/N/Q). Both WT HSCT and LV-mediated HSCGT transplant groups exhibited a 
reduction in β-Hex in somatic tissues. However, significant reductions in β-Hex in the brain 
were only seen in LV-mediated HSCGT groups (Fig. 2K), paralleling the upregulation of 
NAGLU seen in the brain of these animals. 
Normalisation of glycosaminoglycan storage in the brains of LV-mediated HSCGT 
treated mice 
Loss of NAGLU results in the accumulation of partially degraded HS, therefore primary HS 
storage was measured in the liver and brain of control and treated mice to determine the 
effectiveness of therapy (Fig. 3/Supplementary Fig. 3). In the liver a 21-fold increase in HS 
was seen in MPSIIIB mice, which was normalised to near WT levels in both WT HSCT and 
all HSCGT treatment groups (Fig. 3A). However, in the brain, only LV-mediated HSCGT 
groups showed normalised HS storage, with only a marginal non-significant decrease in WT 
HSCT mice (Fig. 3C). A slight decrease in accumulated HS in liver and brain was also seen 
with PRED treatment, but this was non-significant (Fig. 3A).  
Analysis of the HS disaccharide composition revealed abnormalities in several sulphated 
disaccharide units in MPSIIIB mice in both liver (Fig 3B) and brain (Fig 3D). In the brain 76% 
of all disaccharides were N-sulphated (Supplementary Fig. 3B), coupled with 2.7-fold and 2.0-
fold increases in 2-O-sulphation and 6-O-sulphation respectively. Consistent with reductions 
in HS levels, brain HS patterning was only corrected with LV-mediated HSCGT, whereas liver 
HS patterning and sulphation was normalised in all HSCGT and WT HSCT groups (Fig. 
3/Supplementary Fig. 3). These dramatic increases in total HS and in HS sulphation in 
MPSIIIB are likely to present both a physical and functional barrier to normal cellular function. 
Thus normalisation of brain HS storage and patterning following HSCGT should restore HS-
protein binding homeostasis. 
NAGLU enzyme is not directly involved in CS/DS degradation, however secondary storage of 
other lysosomal substrates might be expected, therefore we measured CS/DS in the liver and 
brain of control and treated animals. The main disaccharide CS/DS units found in the liver 
were ΔUA-GalNAc(4S,6S) and ΔUA-GalNAc(4S), with few 2-O-sulphate-containing residues 
(Fig. 3/Supplementary Fig. 3). 6-O-sulphation was significantly increased in MPSIIIB animals 
together with a 4.1-fold increase over WT in total CS/DS. Total CS/DS was significantly 
decreased in the liver of both WT-HSCT and all HSCGT groups and interestingly, also those 
treated with PRED alone (Fig. 3E). Normalisation of 6-O-sulphation levels was also apparent 
in all transplant groups, however CS/DS patterning was not corrected in PRED mice (Fig. 3F), 
despite the decrease in CS/DS burden.  
In the brain, the major CS/DS component is ΔUA-GalNAc(4S) with no detectable 2-O-
sulphation and few 6-O-sulphate containing disaccharides. No secondary storage of CS/DS or 
alterations in CS/DS sulphation were apparent between WT and MPSIIIB animals (Fig. 
3H/Supplementary Fig. 3D).  
Inflammatory cytokines are only reduced in the brain of LV-mediated HSCGT-
treated mice 
Lysosomal accumulation of HS and secondary storage products lead to inflammation, with 
many chemokines/cytokines binding directly to HS, leading to their capture at the cell surface. 
Significant upregulation of MIP-1ɑ, IL-1ɑ, MCP-1 and KC protein was noted in the brain of 
MPSIIIB mice at 8-months of age (Fig. 4A-D). WT HSCT resulted in little or no effect on 
these levels. Prednisolone treatment alone had no effect on these cytokines in the brain. LV-
mediated NAGLU overexpression using either LV-vector in all HSCGT groups resulted in 
complete normalisation of MIP-1ɑ, IL-1ɑ and MCP-1 in the brain (Fig. 4A-C), with expression 
reduced to WT levels.  
A reduction in inflammatory chemokines was also seen in the periphery; liver MIP-1ɑ, IL-1ɑ, 
MCP-1, KC and RANTES and circulating plasma IL-1ɑ, MCP-1 and KC were reduced in all 
LV-mediated HSCGT groups, as well as in WT HSCT mice, probably due to the normalisation 
of HS levels in the periphery. Mice that received the anti-inflammatory prednisolone also 
exhibited significantly suppressed levels of these inflammatory cytokines in the liver and 
plasma, indeed dropping below WT. Additional reductions in cytokine levels were seen with 
PRED+LV.NAGLU in the periphery, suggesting synergistic effects of combined treatments. 
This highlights that although PRED does not appear to directly affect brain inflammation, it 
acts to significantly reduce inflammation in the periphery.  
LV-mediated HSCGT, HSCT and PRED each significantly improve behaviour 
MPSIIIB patients exhibit increasingly severe behavioural problems as a result of accumulating 
neurological damage. To determine whether LV-mediated HSCGT treatment was able to 
ameliorate the behavioural phenotype seen in MPSIIIB mice, the open field test was conducted 
at 6 months of age (4 months post-transplant). Consistent with previous findings, MPSIIIB 
mice display a hyperactive phenotype (Langford-Smith et al., 2011b), behaving significantly 
different from WT in the four parameters tested: total distance moved, frequency of centre 
entries, frequency immobile and average speed (Fig. 4M-P). Interestingly, all treatments, 
including WT HSCT and PRED, where brain inflammation remains high, resulted in full 
correction of these behavioural phenotypes, with animals appearing indistinguishable from WT 
(Fig. 4M-P). Additionally improvement in these behaviours observed in PRED-treated mice, 
was further ameliorated with the addition of LV.NAGLU (Fig. 4M-O), suggesting additional 
benefit with combined treatments.  
Only LV-mediated HSCGT is sufficient to correct astrogliosis and microgliosis in 
the brain 
Maintenance of the neuron-microglia-astrocyte “triad” is critical for normal brain function 
(Cerbai et al., 2012), yet enlarged lysosomes and chronic neuroinflammation with extensive 
microgliosis and astrocytosis is characteristic of MPSIIIB disease (Wilkinson et al., 2012). 
Coronal brain sections were stained with lysosomal associated membrane protein 2 (LAMP2) 
to highlight lysosomal swelling, together with either activated astrocyte marker GFAP (Fig. 
5/Supplementary Fig. 4) or neuronal marker NeuN (Fig. 6). In WT, astrocytic GFAP+ cells 
were largely absent from the cortex, striatum and thalamic regions, although staining was 
clearly visible in the stratum layers of the hippocampus and amygdala (Fig. 5/Supplementary 
Fig. 4). In contrast, significant astrocytosis was apparent throughout the MPSIIIB brain, with 
large numbers of activated astrocytes present in the cortex, striatum and substantia nigra. No 
obvious changes in neuronal cell number were noted between WT and MPSIIIB following 
staining for NeuN, indicating there is little neuronal cell loss in MPSIIIB (Fig. 6).  
In WT brains LAMP2, staining was punctate and more peripheral within neurons, with 
negligible astrocytic expression. MPSIIIB mice however exhibit significantly increased 
LAMP2 staining compared to WT, with intense large vesicular LAMP2+ lysosomes present 
throughout GFAP+ astrocytes and in distinct locations around the nucleus of NeuN+ neurons 
within the cortex, pyramidal regions of the hippocampus and throughout the amygdala (Fig. 
5/6). In the striatum and substantia nigra intense LAMP2 staining appeared restricted to 
GFAP+ astrocytes (Fig. 5). Thus although there is no change in neuronal cell number the 
significant lysosome burden in these cells is likely to dramatically alters cellular function, 
leading to the neurological outcomes noted in these mice. 
PRED treatment resulted in minimal changes in LAMP2 staining or astrocytosis (Fig. 5). A 
small reduction in the intensity of LAMP2 was present in the cortex of WT HSCT mice (Fig. 
5A/C), although no significant decreases in other regions of the brain compared to untreated 
MPSIIIB were apparent. In HSCGT mice treated with LV.NAGLU with or without PRED 
treatment or following treatment with LV.NAGLU-IGFII, significant reductions in LAMP2 
staining were apparent, with little astrocytosis (GFAP+ cells) noted throughout the cortex, 
striatum and all other regions of the brain studied (Fig. 5/Supplementary Fig. 4). LV.NAGLU 
consistently gave greater reductions in lysosomal swelling compared to LV.NAGLU.IGFII but 
both treatments mediated reductions in lysosomal swelling in neurons and astrocytes indicating 
cross-correction.  
Severe neuroinflammation and microgliosis in MPSIIIB is highlighted by a 47-fold increase in 
isolectin B4 (IB4)-positive microglia in the cortex and extensive staining throughout the 
MPSIIIB brain (Fig. 7A-C/Supplementary Fig. 5). WT HSCT resulted in a small, yet 
significant decrease in IB4 staining however levels were still 33-fold over WT. Little effect on 
brain microgliosis was seen with PRED treatment. MPSIIIB mice treated with LV.NAGLU 
with or without PRED resulted in complete reversal of neuroinflammation, with few IB4+ cells 
remaining in the cortex, striatum or hippocampal brain regions (Fig. 7). IB4+ cells did however 
remain in the amygdala, thalamic and substantia nigra regions of the brain in these mice 
(Supplementary Fig. 5), although levels were substantially reduced compared to untreated 
animals. The amygdala is important in memory processing and emotional responses, thus 
reductions in IB4+ cells might be key for amelioration of behavioural issues. The level of 
correction achieved with LV.NAGLU-IGFII was not as pronounced as with LV.NAGLU, 
whereby IB4+ cell numbers remained elevated compared to WT. However, microgliosis in 
LV.NAGLU-IGFII animals was significantly improved compared to untreated and WT HSCT 
(Fig. 7A-C). 
MPS disease is also characterised by secondary storage of other compounds including GM2 
gangliosides in the brain, which may itself propagate CNS inflammatory responses observed 
in GM2 mice (Jeyakumar et al., 2003). WT animals exhibit little GM2 storage in the brain (Fig. 
7D-F/Supplementary Fig. 5). However MPSIIIB animals have distinct punctate storage within 
layers V/VI of the cortex, throughout amygdala and hippocampal regions and in the zona 
incerta. GM2 staining was absent or low in all LV-mediated HSCGT treated mice, appearing 
indistinguishable from WT controls, however only marginal reductions in staining was seen in 
WT HSCT mice. No apparent changes in GM2 staining were seen with PRED treatment alone. 
Therefore staining of the brain for neuroinflammatory markers suggests LV-mediated HSCGT 
can abrogate the disease phenotype in MPSIIIB animals. 
PRED treatment reduces inflammation in the liver 
Although no reduction in inflammation was seen in the brain of PRED treated mice, consistent 
with prednisolone being unable to cross the blood-brain barrier, cytokine analysis suggested 
widespread reductions in inflammatory cytokine expression in the periphery. Therefore liver 
from control and treated mice was stained with IB4 (Fig. 8). Intense IB4 staining was visible 
throughout the liver of untreated MPSIIIB mice compared to WT. PRED treatment resulted in 
significant decreases in IB4-reactivity throughout the liver, with levels similar to WT. WT 
HSCT and HSCGT-treated groups also exhibited significantly reduced IB4+ staining, however 
combined PRED+LV.NAGLU treatment resulted in synergistic results, with levels dropping 
below WT (Fig. 8). This suggests prednisolone may aid reduction in disease pathology in 
somatic organs. 
Discussion 
Here we demonstrate a LV-mediated HSCGT approach to treat neuropathology in Sanfilippo 
disease, providing a promising treatment option for these patients. WT HSCT, although 
providing benefit to somatic organs and increasing life span, provided insufficient NAGLU 
levels in the brain to improve neuropathology, as seen previously (Zheng et al., 2004; 
Heldermon et al., 2010). This is similar to outcomes in Sanfilippo patients, who typically have 
improved lifespan without neurological correction (Vellodi et al., 1992; Prasad et al., 2008). 
In contrast HSCGT with LV.NAGLU-transduced autologous HSCs improved all pathogenic 
markers, resulting in normalisation of primary HS storage, abolition of secondary substrate 
storage materials and significant reductions in inflammatory cytokine expression, lysosomal 
swelling, microgliosis and astrogliosis in the brain. Enzyme levels achieved in somatic organs 
were also far superior to WT HSCT. In this study mice were treated at approximately 2 months 
of age, at which stage considerable disease burden exists (Wilkinson et al., 2012; Ribera et al., 
2015). Thus our LV-mediated HSCGT approach is able to successfully correct disease 
pathology, even when significant neuropathology already exists. Significantly in HSCGT-
treated animals, restoration of brain NAGLU enzyme above ~5% appeared sufficient for 
complete reversal of the MPSIIIB neuropathology at 6 months post-treatment. This is in 
contrast to a retroviral HSCGT approach previously tested in MPSIIIB (Zheng et al., 2004), 
where brain correction was sporadic, with ~25% WT brain enzyme in the highest group, but 
with considerable variability, with brain expression in most animals remaining low. Probable 
gene silencing from the LTR promoter was noted, reflecting the early generation vector design 
and transduction methodology employed. 
C-terminal fusion of IGFII to NAGLU resulted in minimal NAGLU secretion into the culture 
medium of CHME3 microglial cells in vitro or into blood plasma in vivo. This is in contrast to 
previous results in Chinese hamster ovary cells (Kan et al., 2014b), yet considering the identical 
linker was used, this most likely reflects the differences in cell types used. Regardless, it is 
typically assumed that cross-correction is the major mechanism for disease correction and is 
essential for treatment efficacy. However, restricting expression of NAGLU to the engrafted 
donor macrophages in the brain and thus limiting cross-correction with LV.NAGLU-IGFII, 
surprisingly resulted in significant reductions in neuropathology, with near identical outcomes 
to using the unmodified LV.NAGLU vector. Although we cannot exclude that some cross-
correction remains, and that the IGFII linker may enhance uptake (Kan et al., 2014b), despite 
reduced secretion, as observed by reductions in neuronal and astrocytic LAMP2, these data 
nevertheless suggest that correction of donor macrophages may prove as important for efficient 
brain correction as widespread dissemination of NAGLU to all cell types in the brain.  
We were surprised that WT HSCT and PRED were able to improve hyperactivity, correcting 
behavioural phenotypes seen in MPSIIIB mice. However this is consistent with previous 
findings in which treatment of MPSIIIB mice where prednisolone improved performance in 
the Morris Water Maze, significantly reduced spleen size and decreased T-cell activation 
(DiRosario et al., 2009). Whereas WT HSCT effectively delivers NAGLU enzyme to somatic 
organs, abolishing accumulated HS and thereby restoring lysosomal function, the 
corticosteroid prednisolone acts as an anti-inflammatory. Common to both treatments is 
significantly reduced inflammation in the periphery, but without central brain effects. Several 
other studies have indicated that correction of somatic inflammation has the potential to treat 
disorders of neurodevelopmental origin. For example in the lysosomal storage disease infantile 
neuronal ceroid lipofuscinosis, intraperitoneal injections of MW151, a small-molecule anti-
neuroinflammatory, was able to reduce the incidence of seizures, despite having little effect on 
brain pathology (Macauley et al., 2014). Prednisolone itself is not recommended as a long-term 
treatment for patients due to deleterious side effects. However, our data linking a decrease in 
circulating inflammatory cytokines with improved behaviour indicates that treatments with a 
similar action to prednisolone may provide relief from at least some of the behavioural aspects 
of MPSIIIB disease, and has the potential to be an adjunct therapy. Although LV-mediated 
HSCGT alone appears sufficient to correct the CNS pathology, the benefits of prednisolone to 
somatic disease indicates that specifically targeted anti-inflammatories could be incorporated 
into therapeutic approaches for MPSIIIB. 
Several other strategies to treat MPSIIIB patients are being trialled. Intracerebroventricular 
injection of NAGLU enzyme has proven effective in mouse models of MPSIIIB (Kan et al., 
2014a) but clinical application of this approach in MPS II has been fraught with device failure 
issues (Muenzer et al., 2016), with half of the enrolled patients required surgical intervention 
due to delivery device failure. A similar trial for MPSIIIA was unsuccessful (Jones et al., 2016). 
A systemic gene therapy approach using intravenous injection of AAV9 in mice at 1 month of 
age was reported to achieve greater than 2-fold over WT brain enzyme delivery, together with 
somatic NAGLU expression, glycosaminoglycan reduction and behavioural correction (Fu et 
al., 2011; Fu et al., 2017). This approach has now been approved for a phase 1/2 clinical trial 
in MPSIIIB patients (IND 16671). Nonetheless scalability remains a major challenge, requiring 
a significant change in manufacturing infrastructure to enable the synthesis of sufficient virus 
at the magnitude required to treat patients.  
Targeted injection of AAV-NAGLU vectors directly into the brain of MPSIIIB mice has also 
been tested, leading to long-term NAGLU expression, reduced glycosaminoglycan levels and 
some behavioural improvements (Fu et al., 2002; Cressant et al., 2004; Fu et al., 2007; Fu et 
al., 2010; Heldermon et al., 2010; Heldermon et al., 2013). However cellular transduction was 
often restricted to those cells surrounding the injection site and systemic organs remain 
uncorrected, something that is overcome by our HSCGT approach, as donor macrophages 
distribute and engraft throughout the brain and somatic organs (Wilkinson et al., 2013). 
Interestingly in some studies survival was increased to 19-20 months for some animals, above 
what we achieve here with HSCGT. The significance of survival is however not clear in 
MPSIIIB, where the main disease pathology is in the brain. In the absence of significant 
neuronal cell death in the mouse model, the endpoint is typically urine retention (Gografe et 
al., 2009). Scalability with the AAV approach does seem to be problematic, with substantial 
increases in vector distribution and injection sites required for significant success in patients 
(Tardieu et al., 2017). An alternative is direct injection of AAV9-NAGLU into cerebrospinal 
fluid, reported to result in widespread CNS-targeting and some somatic correction via vector 
passage into circulation (Ribera et al., 2015). The high rate of pre-existing immunity to AAV 
vectors in the human population however provides a significant obstacle for therapy, with 
patients often positive for neutralising-antibodies against multiple serotypes (Hareendran et al., 
2013). Generation of novel AAV-serotypes is therefore essential. 
In summary, here we present neurological disease correction of MPSIIIB mice by LV-mediated 
HSCGT, with significantly enhanced correction compared to WT HSCT. Critically LV-
mediated HSCGT is relevant and scalable to MPSIIIB patients. Thus given the current lack of 
effective treatment for MPSIIIB, this study demonstrates that HSCGT alone or in combination 
with anti-inflammatories could be a clinically viable approach to improve the neurological 
function in MPSIIIB patients. 
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Figure Legends 
Figure 1: Efficient expression of NAGLU from lentiviral vectors enhances survival 
following HSCGT. 
A: Schematic of pCCL lentiviral vectors engineered to express either codon-optimised 
NAGLU or NAGLU-IGFII fusion proteins under the control of the internal CD11b promoter. 
B/C: Intracellular (B) or extracellular (C) NAGLU enzyme activity per LV-copy in the human 
CHME3 microglial cell line 48 hours after transduction at an MOI of 10. D: Groups used for 
in vivo study. Groups 1 (WT) and 2 (MPSIIIB) are untreated control animals. In group 3 
myeloablated two month old MPSIIIB mice received WT HSCT using whole BM. In group 4 
two month old myeloablated MPSIIIB mice were transplanted with HSC-enriched MPSIIIB 
BM transduced with LV.NAGLU. In group 5 myeloablated MPSIIIB mice received HSC-
enriched MPSIIIB BM which had been transduced with LV.NAGLU-IGFII. Group 6 mice 
received prednisolone delivered in drinking water from 2 months of age. A combined therapy 
was delivery to group 7 whereby myeloablated MPSIIIB mice received HSC-enriched BM 
transduced with LV.NAGLU at 2 months of age, followed by prednisolone delivered in 
drinking water (PRED+LV.NAGLU). Thus groups 4, 5 and 7 (LV.NAGLU, LV.NAGLU-
IGFII and PRED+LV.NAGLU) all received LV-mediated HSCGT treatments. WBC analysis 
and behaviour was performed on all mice at 6 months of age. 6-10 mice were harvested at 8 
months (6 months post-transplant) for biochemical and histological analysis. A cohort (n=10-
18) were kept for survival and sacrificed at their humane endpoint. E/F: VCN (E) and NAGLU 
enzyme activity (F) of HSC-enriched MPSIIIB BM used for transplants. G/H: LV-transduced 
HSC-enriched MPSIIIB BM cells at transplant were cultured for 12 days in methylcellulose 
culture, counting the resulting colony types (G). Total colony numbers per 2500 cells plated is 
shown in H. I: Donor chimerism in WBCs was determined using flow cytometry at 6 months 
post-transplant. J: Kaplan–Meier survival curve. A cohort of 10-18 mice per group were kept 
for long term analysis and sacrificed at their humane endpoint. In untreated MPSIIIB and 
PRED treated mice this was typically due to urine retention. K: Mean survival in months for 
each group. Significance is indicated by lines with *P < 0.05, **P < 0.01, ***P < 0.001 and 
****P < 0.0001. 
Figure 2: Superior NAGLU expression in all tissues including the brain is achieved with 
LV-mediated HSCGT compared to WT HSCT. 
VCN (A, F, I, L and O), NAGLU activity (B, D, G, J, M and P) and β-Hex activity (C, E, H, 
K, N, Q) measured in WBCs, plasma, BM, brain, spleen and liver of mice at 8 months of age 
following the indicated treatment. LV.NAGLU, LV.NAGLU-IGFII and PRED+LV.NAGLU 
are all LV-mediated HSCGT-treated groups. Error bars represent the SEM. Significant 
differences were calculated using a one-way Anova, *P < 0.05, **P < 0.01, ***P < 0.001 and 
****P < 0.0001. Significance to WT is shown above bars, all other comparisons are shown 
using a line. 
Figure 3: Primary and secondary storage of HS and CS/DS is significantly reduced with 
LV-mediated HSCGT. 
A-D: Glycosaminoglycan chains were extracted from the liver and brain of 8 month old mice 
following the indicated treatment and digested with heparinases I, II and III. Resultant 
disaccharides were AMAC-labelled and analysed by RP-HPLC. Total HS was measured and 
quantified to µg HS per mg of total protein in the liver (A) and brain (C). Relative percentage 
contribution of each HS disaccharide species in liver (B) and brain (D) was also calculated. E-
G: Total CS/DS was measured following RP-HPLC of AMAC-labelled disaccharides 
generated following cABC treatment of isolated glycosaminoglycans from the liver (E) and 
brain (G). Amounts were quantified to µg CS/DS per mg of total protein. Relative percentage 
contribution of each CS/DS disaccharide species in liver (F) and brain (H) was measured. 
LV.NAGLU, LV.NAGLU-IGFII and PRED+LV.NAGLU are all LV-mediated HSCGT-
treatment groups. Error bars represent the SEM. Significant differences were calculated using 
a two-way Anova using Tukey post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P 
< 0.0001. Significance to WT is shown above bars, all other comparisons are illustrated using 
a line. 
Figure 4: Reduction in inflammation and behavioural hyperactivity correction in 
MPSIIIB treated mice. 
A-D: Quantification of cytokines MIP-1ɑ (A), IL-1ɑ (B), MCP-1 (C) and KC (D) in the brain 
at 8 months of age in the indicated treatment groups. E-I: Quantification of cytokines MIP-1ɑ 
(E), IL-1ɑ (F), MCP-1 (G), KC (H) and RANTES (I) in the liver of treated mice. J-L: IL-1ɑ 
(J), MCP-1 (K) and KC (L) in plasma. M-P: Open field behaviour was performed for one hour 
at the same point of the circadian rhythm at 6 months of age (n = 14-22 female mice per group). 
The measures of hyperactivity were average speed (M), distance moved (N), frequency in 
centre (O) and frequency immobile (P). LV.NAGLU, LV.NAGLU-IGFII and 
PRED+LV.NAGLU are all LV-mediated HSCGT-treatment groups. Error bars represent the 
SEM. Significant difference to WT is demonstrated with *P < 0.05, **P < 0.01, ***P < 0.001 
and ****P < 0.0001. Other differences are indicated with a line. 
Figure 5: Correction of astrocytic lysosomal swelling and astrocytosis following LV-
mediated HSCGT but not following WT HSCT or PRED treatment. 
A: LAMP2 (green), GFAP (red) and DAPI (nucleus, blue) staining in the cortex (covering 
layers IV/V/VI, -1.06 relative to bregma), striatum (0.14 relative to bregma), hippocampus (-
1.70 relative to bregma) and amygdala (-1.70 relative to bregma) in control and transplant-
treated mice. LV.NAGLU, LV.NAGLU-IGFII and PRED+LV.NAGLU are all LV-mediated 
HSCGT-treatment groups. Representative images are shown following staining of 6-10 mice 
per group. Scale bar = 50µm. B/C: Quantification of GFAP (B) and LAMP2 (C) staining using 
ImageJ. 2 cortex regions (x20, −0.46 and -1.06 relative to bregma) were processed per brain. 
Error bars represent the SEM. Significant difference to WT is demonstrated with *P < 0.05, 
**P < 0.01, ***P < 0.001 and ****P < 0.0001. Other differences are indicated with a line. 
Figure 6: Neuronal LAMP2 is significantly reduced with LV-mediated HSCGT but not 
following WT HSCT or PRED treatment. 
Representative images of LAMP2 (green), NeuN (red) and DAPI (nucleus, blue) staining in 
the cortex that correspond to a whole field of view covering cortical layers IV/V/VI (-1.06 
relative to bregma), striatum (0.14 relative to bregma), hippocampus (-1.70 relative to bregma) 
and amygdala (-1.70 relative to bregma) in control and transplant mice. Representative images 
are shown following staining of 6-10 mice per group. LV.NAGLU, LV.NAGLU-IGFII and 
PRED+LV.NAGLU are all LV-mediated HSCGT-treatment groups. Scale bar = 50µm. 
Figure 7: Correction of brain microgliosis and secondary storage with LV-mediated 
HSCGT but not with WT HSCT or PRED treatment. 
A: IB4-positive microglia (brown) and nuclei (blue) in the cortex (layers II-VI, -1.06 relative 
to bregma), striatum (0.14 relative to bregma) and hippocampus (-1.70 relative to bregma) in 
control and transplant-treated mice. Representative images are shown following staining of 6-
10 mice per group. Scale bar = 100µm. B/C: Cell counts of IB4-positive cells in the cortex (B) 
or striatum (C). For cortical staining, cells were counted from two fields of view (x20 objective) 
per brain section, four sections per mouse (at bregma 0.14, -0.46, -1.06 and -1.7). Two fields 
of view were counted from the striatum at 0.98 and 0.14 relative to bregma. 6-10 mice were 
counted per group. D: GM2 ganglioside (black) staining of the cortex (layers IV-VI, -0.46 
relative to bregma), amygdala (-1.70 relative to bregma) and hippocampus (-1.70 relative to 
bregma). Scale bar = 50µm. E/F: Cell counts of GM2-positive cells in the cortex (E) or 
amygdala (F). LV.NAGLU, LV.NAGLU-IGFII and PRED+LV.NAGLU are all LV-mediated 
HSCGT-treatment groups. Error bars represent SEM. Significant difference to WT is 
demonstrated with *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Other differences 
are indicated with a line. 
Figure 8: PRED treatment reduces microgliosis in the liver. 
IB4 staining (brown) and nucleus (blue) in the liver. Scale bar = 100 µm. Quantification of 
staining is shown using CaseViewer, measuring 8 fields of view (0.5 x 0.5µm) per mouse. 
LV.NAGLU, LV.NAGLU-IGFII and PRED+LV.NAGLU are all LV-mediated HSCGT-
treatment groups. Error bars represent SEM. Significant difference to WT is demonstrated with 
*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Other differences are indicated with 
a line. 
  
Supplementary Figure Legends: 
Supplementary Figure 1: BM CFU numbers and type are unaffected in LV-mediated 
HSCGT animals. 
At 8 months animals were sacrificed and the BM extracted. BM was cultured for 12 days in 
methylcellulose culture, counting the resulting colony types (A). Total number of colonies per 
16,667 cells plated is shown (B). LV.NAGLU, LV.NAGLU-IGFII and PRED+LV.NAGLU 
are all LV-mediated HSCGT-treatment groups. 
Supplementary Figure 2: Linear relationship between VCN and enzyme activity.  
Plot of VCN against NAGLU enzyme activity in the indicated organs. The relationship 
between VCN and enzyme activity is shown using a linear regression with 95% confidence 
limits.  
Supplementary Figure 3: Restoration of WT HS patterning following LV-mediated 
HSCGT. 
A/B: Relative proportion of HS that was N-sulphated (NS), N-acetylated (NAc), 6-O-sulphated 
(6S), or 2-O-sulphated (2S) in liver (A) and brain (B) calculated from disaccharide composition 
following heparinase I/II/III digestion, AMAC labelling and RP-HPLC (Fig. 3). C/D: Relative 
proportion of CS/DS that was 2-O-sulphated (2S), 4-O-sulphated (4S) or 6-O-sulphated (6S) 
in liver (C) and brain (D) calculated from disaccharide composition analysis following cABC 
digestion, AMAC labelling and RP-HPLC (Fig. 3). LV.NAGLU, LV.NAGLU-IGFII and 
PRED+LV.NAGLU are all LV-mediated HSCGT-treatment groups. Error bars represent the 
SEM. Significant differences demonstrated with *P < 0.05, **P < 0.01, ***P < 0.001 and 
****P < 0.0001. 
Supplementary Figure 4: LAMP2 remains slightly elevated in the thalamus but is 
significantly reduced in the substantia nigra following LV-mediated HSCGT treatment. 
LAMP2 (green), GFAP (red) and DAPI (nucleus, blue) staining in the thalamus and substantia 
nigra of control and transplant mice. Representative images are shown following staining of 6-
10 mice per group. LV.NAGLU, LV.NAGLU-IGFII and PRED+LV.NAGLU are all LV-
mediated HSCGT-treatment groups. Scale bar = 50µm. 
Supplementary Figure 5: Correction of microgliosis and GM2 secondary storage in other 
brain regions by LV-mediated HSCGT. 
A: Isolectin B4-positive microglia (brown) and nuclei (blue) in the thalamus, amygdala and 
substantia nigra in control and transplant-treated mice. Representative images are shown 
following staining of 6-10 mice per group. Scale bar = 100µm. B: GM2 secondary storage 
(black) in the zona incerta. Representative images are shown following staining of 6-10 mice 
per group. LV.NAGLU, LV.NAGLU-IGFII and PRED+LV.NAGLU are all LV-mediated 
HSCGT-treatment groups. Scale bar = 50µm. 
Supplementary Table 1: AMAC correction factors. 
Disaccharide AMAC correction factor 
ΔUA(2S)-GalNAc(4S, 6S) 1.38 
ΔUA(2S)-GalNAc(4S) 1.35 
ΔUA-GalNAc(4S, 6S) 1.50 
ΔUA-GalNAc(4S) 1.43 
ΔUA-GalNAc(6S) 1.35 
ΔUA-GalNAc 1.40 
ΔUA(2S)-GlcNS6S 1.25 
ΔUA-GlcNS(6S) 1.13 
ΔUA(2S)-GlcNS 1.00 
ΔUA-GlcNS 1.04 
ΔUA-GlcNAc(6S) 1.13 
ΔUA-GlcNAc 1.08 
 













